💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Narayana Hrudayalaya Limited is engaged in medical and healthcare services. The Company operates a network of multispecialty and super-specialty hospitals across multiple locations. Its operating segment is Medical and Healthcare Related Services. Its medical services include…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, slow-growing business, priced for perfection.
Narayana Hrudayalaya is scored on the pharma / healthcare framework. It keeps a healthy 10.1% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 2.01× reported profit. Free cash flow is worth about -5.3% of its market value.
Over the last 3 years revenue compounded at 20%/yr and profit at 10%/yr. Book value itself has compounded 29%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 17.2%. In the latest quarter profit grew 45% versus the prior quarter.
At 48× earnings, the stock sits at the 87th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price already implies ~20%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 45.25 | 75.46 | better |
| P/B | 7.77 | 3.5 | worse |
| EV/EBITDA | 21.91 | 19.83 | worse |
| ROE | 17.17 | — | — |
| ROCE | 12.26 | 10.78 | better |
| ROA | 6.43 | 3.84 | better |
| Quick Ratio | 2.07 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 20% CAGR over 3 years — high-growth territory. Growth is accelerating — latest year outpaced the prior year's rate.
Revenue is outpacing profit (20% vs 10%) — costs are rising faster than the top line.
Operating margin has compressed from 16% to 12% — costs or competition are eating into profitability.
ROE at 18% — a respectable return on shareholder capital. Capital efficiency declining — ROE down 11pp.
10% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 2.0× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 6% sequentially — momentum is building. Run-rate stepping up — recent quarters average 17% above earlier ones.
Profit jumped 45% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (6% → 10%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 63.3% — majority control intact. FIIs trimmed 2.1pp — foreign money is rotating out. MF holding up 2.4pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.